Scarica l'app Stockscreener
0.8253
8.14%
-0.0731
Dopo l'orario di chiusura:
.83
0.0047
+0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Precedente Chiudi:
$0.8984
Aprire:
$0.9
Volume 24 ore:
4.15M
Relative Volume:
0.61
Capitalizzazione di mercato:
$183.23M
Reddito:
$2.04M
Utile/perdita netta:
$-43.21M
Rapporto P/E:
-3.9927
EPS:
-0.2067
Flusso di cassa netto:
$-105.93M
1 W Prestazione:
-9.31%
1M Prestazione:
+16.21%
6M Prestazione:
-29.46%
1 anno Prestazione:
-62.99%
Intervallo 1D:
$0.82
$0.90
Intervallo di 1 settimana:
$0.82
$1.22
Portata 52W:
$0.5469
$2.93
Humacyte Inc Stock (HUMA) Company Profile
Nome
Humacyte Inc
Settore
Industria
Telefono
919-313-9633
Indirizzo
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.8253 | 199.46M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-27 | Iniziato | Barclays | Overweight |
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2023-12-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-14 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Iniziato | Cowen | Outperform |
| 2021-09-24 | Iniziato | Oppenheimer | Outperform |
| 2021-09-22 | Iniziato | BTIG Research | Buy |
| 2021-09-16 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Humacyte Inc Borsa (HUMA) Ultime notizie
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization - Insider Monkey
[144] Humacyte, Inc. SEC Filing - Stock Titan
Humacyte, Inc. (HUMA) reports Q1 loss, misses revenue estimates - MSN
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMA - TradingView
HUMA Should I Buy - Intellectia AI
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Humacyte, Inc. (HUMA) stock declines while market improves: Some information for investors - MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Does Humacyte’s (HUMA) Nasdaq Notice Quietly Reframe Its Financing Flexibility And Clinical Adoption Story? - simplywall.st
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target - Investing.com UK
Humacyte, Inc. (NASDAQ:HUMA) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target By Investing.com - Investing.com South Africa
Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
HUMACYTE ($HUMA) Releases Q1 2026 Earnings - Moomoo
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $1.5 - Moomoo
HUMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Humacyte (NASDAQ: HUMA) posts Q1 2026 loss and flags going concern risk - Stock Titan
MSN Money - MSN
Humacyte, Inc. Stock 12‑Month Price Target Cut to $4.93, Implies 442% Upside - TradingView
Humacyte (HUMA) Q1 2026 Earnings Transcript - The Globe and Mail
Humacyte Q1 2026 Earnings Call Transcript - MarketBeat
BTIG cuts Humacyte stock price target on revenue miss, slower ramp - Investing.com
BTIG cuts Humacyte stock price target on revenue miss, slower ramp By Investing.com - Investing.com South Africa
Humacyte Q1 Earnings Call Highlights - MarketBeat
HUMA: Symvess sales surged, restructuring cut costs, and key clinical milestones are on track for 2026 - TradingView
Humacyte Releases Q1 2026 Financial Results - AlphaStreet
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript - Yahoo Finance
Earnings call transcript: Humacyte Q1 2026 EPS beats forecast, revenue misses - Investing.com
HUMA: Symvess sales surged year-over-year, with restructuring and global expansion positioning for growth - TradingView
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
HUMA: Symvess sales grew, net loss widened, and restructuring cut costs as global expansion advanced - TradingView
Bioengineered blood vessel firm wins Saudi deal and Pentagon backing - Stock Titan
Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ... By GuruFocus - Investing.com Canada
Humacyte Q1 2026 earnings preview - MSN
Humacyte appoints Todd Rasmussen as chief surgical officer By Investing.com - Investing.com South Africa
Humacyte appoints Dr. Todd E. Rasmussen as chief surgical officer - marketscreener.com
Humacyte appoints Todd Rasmussen as chief surgical officer - Investing.com
Humacyte Appoints Todd E. Rasmussen, M.D., as Chief Surgical Officer to Advance Clinical Adoption of Symvess - Quiver Quantitative
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer - The Manila Times
Humacyte Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HUMAW | Humacyte, Inc. Warrant Insider Trading - Quiver Quantitative
Humacyte Inc Azioni (HUMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):